Immunotherapy in Advanced NMSC: Treatment Selection and Collaborative Care

Program Overview

This activity features an interprofessional, multidisciplinary panel of experts offering privileged insights on evidence-based immunotherapy selection and collaborative care in advanced cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC).

0.25 CE Credit(s)
Expires: April 5, 2023

Target Audience

This activity is intended for dermatology and medical oncology clinicians (MD/DO/NP/PA) involved in the care of patients with nonmelanoma skin cancers (NMSC).

Educational Objectives

Upon successful completion of this educational activity, participants should be better able to:

Upon completion of this activity, participants should be better able to:

  • Select appropriate immunotherapy for patients with advanced nonmelanoma skin cancer (NMSC) based on current safety and efficacy data
  • Integrate the unique roles and responsibilities of the interprofessional care team when managing patients with advanced NMSC

Activity Faculty

Vishal Anil Patel

Vishal Anil Patel, MD, FAAD, FACMS

Director, Cutaneous Oncology, GW Cancer Center
Director, Dermatologic Surgery, GW Department of Dermatology
Assistant Professor, Dermatology & Hematology/Oncology
Washington, DC

David M. Miller,

David M. Miller, MD, PhD, FAAD

Medical Oncologist, Dermatologist
Massachusetts General Hospital
Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multi-Disciplinary Clinic
Department of Medicine, Division of Hematology/Oncology
Department of Dermatology
Massachusetts General Cancer Center
Boston, MA

Krista M. Rubin,

Krista M. Rubin, MS, RN, FNP-BC

Nurse Practitioner, Center for Melanoma
Massachusetts General Hospital
Boston, MA


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources